Development and Characterization of a Luciferase Labeled, Syngeneic Murine Model of Ovarian Cancer.

Russell, Shonagh; Lim, Felicia; Peters, Pamela N; Wardell, Suzanne E; Whitaker, Regina; Chang, Ching-Yi; Previs, Rebecca A; McDonnell, Donald P

Russell, Shonagh; Lim, Felicia; Peters, Pamela N; Wardell, Suzanne E; Whitaker, Regina; Chang, Ching-Yi; Previs, Rebecca A; McDonnell, Donald P.

Afiliación

Russell S; Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC 27710, USA.
Lim F; Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC 27710, USA.
Peters PN; Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Duke University School of Medicine, Durham, NC 27710, USA.
Wardell SE; Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC 27710, USA.
Whitaker R; Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Duke University School of Medicine, Durham, NC 27710, USA.
Chang CY; Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC 27710, USA.
Previs RA; Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Duke University School of Medicine, Durham, NC 27710, USA.
McDonnell DP; Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC 27710, USA.

Cancers (Basel) ; 14(17)2022 Aug 30.

Article en En | MEDLINE | ID: mdl-36077756

Palabras clave

STOSE; high-grade serous; immune profiling; immunotherapy; intraperitoneal; murine; ovarian cancer; ovarian intrabursal; syngeneic

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Cancers (Basel) Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google